cemsidomide
cemsidomide: developed by 1 company · 3 clinical trials tracked.
cemsidomide evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could cemsidomide → CCCC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| C4 Therapeutics, Inc. (CCCC) Multiple Myeloma; Multiple Myeloma (MM) | Phase 1 |
Clinical Trials (3)
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)
A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Primary endpoint: Safety and tolerability of cemsidomide in combination with elranatamab
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Primary endpoint: Phase 1: Safety and tolerability of cemsidomide
Frequently asked questions
Who is developing cemsidomide?
cemsidomide is being developed by C4 Therapeutics, Inc..
How many clinical trials involve cemsidomide?
BioSniper tracks 3 clinical trials involving cemsidomide.